HSI1 23,753.84 0.00 --
HSCEI1 7,981.54 0.00 --
Back    Zoom +    Zoom - Block Traded
UBS: AKESO (09926.HK) Partner Receives FDA Complete Response Letter for ivonescimab Plus Chemotherapy BLA, Slightly Negative
2026-11-16 10:52:41
UBS published a research report stating that AKESO (09926.HK)'s partner Summit Therapeutics Inc. (SMMT.US) received a Complete Response Letter from the US FDA regarding the BLA for ivonescimab combined with chemotherapy for non-small cell lung cancer (NSCLC) after TKI treatment. The broker viewed the development as slightly negative, but said it would create sentiment pressure.

UBS noted that the main reason was the failure to achieve statistical significance for the overall survival (OS) endpoint. The broker estimated peak sales for this indication at RMB550 million, accounting for only 1% of ivonescimab's total overseas sales.

The broker believed the key catalyst remains H-3, namely the progression-free survival (PFS) event count for the first-line squamous NSCLC cohort, which is expected to reach the target in 4Q26. UBS maintained its Buy rating and HKD149 target price on AKESO (09926.HK). (da/u)~

AASTOCKS Financial News
Website: www.aastocks.com


This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.